Navigation Links
Amo Phaco Model Diplomax

ProductsAmo Phaco Model Diplomax
Company Diagnostic Instrument Group
Item Amo Phaco Model Diplomax
Features Fluidic balance is controlled via microcomputer which drives the pump, Phaco and I/A can be fine-tuned by changing the footswitch settings, ultrasound power can be turned on and off, at the console or via the optional total remote control, this system is the ideal match for either the hospital or ASC setting, its simple to program, offers easy-to-follow on-screen directives for nursing staff and provides instantaneous status updates via the display screen.
Description Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in an efficient energy transfer.
Info Diagnostic Instrument Group
Customer Service: (877) 344-8733

Related medicine products :

1. Kellan Phaco Manipulator
2. Koch Phacoemulsification Spatula - Rounded Tip w / notch
3. Thornton Phacoemulsification Spatula
4. Koch Phacoemulsification Spatula
5. BD Beaver Phaco slit blade
6. Odyssey Phacoemulsification System
7. SIStem Phacoemulsification System
8. Precisionist Phacoemulsification System
9. Photon Laser Phacoemulsification System
10. Phaco-Emulsification System
11. Compact Ultrasonic Phacoemulsification System
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast.
Albumin reagent is used for the quantitative determination of albumin concentration in human serum.
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum.
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen
Medicine Products:
(Date:5/15/2008)... Texas, May 15 /PRNewswire/ -- LifeCare Holdings, ... results for the first quarter,ended March 31, 200...e increased by $6.4 million, or 7.8%, for,the thre...om $82.4 million,for the comparable period in 2007....0%, greater than the same period in 2007., The i...
(Date:5/15/2008)...VER, May 15 /PRNewswire-FirstCall/ - QLT Inc. (NAS...igned a sale and purchase agreement to,sell the la...ers and an,adjacent undeveloped parcel of land in ...losing of the transaction, QLT will enter into a,f...e its operations., "We are very pleased that our ...
(Date:5/15/2008)...ICSBURG, Pa., May 15 /PRNewswire/ -- Select Medica...or its first quarter ended March 31,2008., For t...ng revenues,increased 17.4% to $548.3 million comp... year. Income from operations decreased 9.9% to $5... quarter, prior year. Net income,decreased 47.9% t...
(Date:5/15/2008)...ON, D.C. -- May 15, 2008 -- The Society for Cardi...ay announced that it will hold its 2009 Annual Sci... Las Vegas. The focused, collegial interventional ... early March meeting time beginning in 2010. , T...e premier interventional cardiology meeting of the...
Breaking Medicine News(10 mins):Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 4Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 5Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 6Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 7Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 8Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 9Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2
...ments have proven in recent studies that they are ... // some of the altered functions of the heart acc...Journal of the American College of Cardiology, Oct...n that PUFA helps to reduce the intensity of some ...
...ay announced the publication of pioneering researc...ism of action of the protein RhoH GTPase in the de...immune system. The findings, along with other stud...t for therapeutic intervention in some types of le...
... between celiac disease, a digestive condition tri...r other forms of cognitive decline. The investigat...ical histories of a group of patients with a commo...shed in the October issue of Archives of Neurology...
...out a stomach-stapling surgery by introducing a tu... Around 1 million bariatric surgeries have been ca...ended for weight loss and it involves stapling of ... smaller, as a result, people eat less. “Doing th...
Other Medicine News:Health News:Potential Target for Leukemia Treatment 2Health News:Potential Link Between Celiac Disease and Cognitive Decline 2Health News:NOTE surgery – to combat obesit 2
(Date:5/15/2008)...SE, France, May 15 /- Cerenis,Therape...l company,developing HDL-related compounds for the...s, today announced that it has completed a Phase I...lead product candidates.,CER-002 is a peroxisome p...ic agonist in development for the treatment of car...
(Date:5/15/2008)...s for an Antiplatelet Therapy that, Combined, with...n of Plavix/Iscover and Aspirin, According to ...ss., May 15 /- Decision Resources, on...ms for pharmaceutical and,healthcare issues, finds...provement in patient compared to Sanofi-Aventis/Br...
(Date:5/15/2008)...Newswire/ -- Omega 3 fatty acids bound to,phosphol...ble natural,alternative and may have beneficial ef...vo French study reveals. While several studies hav...ctivity, French researchers have,hypothesized that... on,impulse control., These research findings hav...
(Date:5/14/2008)...y 14 /- Revolution Health and,Emergin...ffer patients and,physicians the largest personali...rvice in the United States. Individuals can quickl...inical trial listings in a confidential,and effici...ing a clinical,trial specialist. The service, powe...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service 2Hologic Announces Two For One Stock Split 10546 1Hologic Announces Two For One Stock Split 10546 2Hologic Announces Two For One Stock Split 10546 3High Dose Chemo Helps Beat Rare Brain Cancer 10544 1High Dose Chemo Helps Beat Rare Brain Cancer 10544 2High Dose Chemo Helps Beat Rare Brain Cancer 10544 3Stryker to Present at Investor Conference 10539 1Stryker to Present at Investor Conference 10539 2Gene variant linked to moderated symptoms of beta thalassemia 10535 1Gene variant linked to moderated symptoms of beta thalassemia 10535 2
...t tolerance observed in Genotype,1 patients suppor...y therapy, WASHINGTON, May 21, 2007 /PRNewswire/ -...opharmaceutical company, today announced,the prese...aring,the combination of injectable omega interfer...tment-naive patients with genotype 1,chronic hepat...
..., 2007 - Results from a new,study, presented at th...nce, showed that more than 99 percent of patients ... were treated,successfully with PEGASYS(R) (pegint...en years later - validating the use of,the word "c...dy,authors. Currently, the best indicator of treat...
Other Medicine Technology:Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 2Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 2Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 5Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 6